EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients

Yu-Xuan Song, Guang-Jun Song, Hui Ma, Bo Feng, Yan-Di Xie iD

The Korean Journal of Gastroenterology · 2025

DOI: 10.4166/kjg.2024.140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Korean Journal of Gastroenterology, 2025. Verfasst von Yu-Xuan Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseas…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Tenofovir, Adenine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Major Project during the 13th Five-Year Plan Period, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: This study assessed the long-term efficacy and safety of tenofovir alafenamide (TAF) in real-world settings.

Methods

Patients who were candidates for TAF treatment and were followed up at 12-week intervals over 192 weeks were enrolled in this study.

Results

One hundred and forty-four patients (50 treatment-naive and 94 treatment-experienced) were included in this study. The cumulative incidence rates of cirrhosis and hepatocellular carcinoma at 192 weeks were 3.9% and 0.7%, respectively. In treatment- naive patients, the rates of a virological response, HBeAg conversion, and HBsAg loss at 192 weeks were 100%, 33.3%, and 2%, respectively. The treatment-naive patients exhibited higher baseline HBsAg levels than the treatment-experienced patients (4.31 log10IU/mL vs. 3.97 log10IU/mL). A significant decrease in the HBsAg levels from the baseline was observed at 144 and 192 weeks in the treatment-naive patients (p=0.01). The baseline body mass index (BMI)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicAntiviral AgentsTenofovirAdenineHumansMaleFemaleMiddle AgedAdultHepatitis B Surface AntigensHepatitis B e AntigensTreatment OutcomeLiver CirrhosisAlanineLiver NeoplasmsCarcinoma, HepatocellularBody Mass IndexHepatitis B virusTriglyceridesDNA, Viral

Stichwörter der Autor:innen

Chronic hepatitis BEfficacyKidney injuryTenofovir

Substanzen

tenofovir alafenamideAntiviral AgentsHepatitis B Surface AntigensTenofovirHepatitis B e AntigensAdenineAlanineTriglyceridesDNA, Viral

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology…

ORCID-Profile: Yan-Di Xie

Förderung

  • National Major Project during the 13th Five-Year Plan Period
  • National Natural Science Foundation of China

Zitieren

APA

Song, Y. X., Song, G. J., Ma, H., Feng, B., & Xie, Y. D. (2025). Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients. The Korean Journal of Gastroenterology. https://doi.org/10.4166/kjg.2024.140

Vancouver

Song YX, Song GJ, Ma H, Feng B, Xie YD. Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients. The Korean Journal of Gastroenterology. 2025. doi:10.4166/kjg.2024.140

BibTeX
@article{Song2025,
  author = {Song, Yu-Xuan and Song, Guang-Jun and Ma, Hui and Feng, Bo and Xie, Yan-Di},
  title = {Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients},
  journal = {The Korean Journal of Gastroenterology},
  year = {2025},
  doi = {10.4166/kjg.2024.140}
}
Kostenlos starten →